Ginkgo Bioworks Holdings Stock
Ginkgo Bioworks Holdings, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Jason Kelly
- Employees
- 485
- Market cap
- $692 M
- IPO
- 19/04/2021
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising…
Ginkgo Bioworks Holdings stock: price history
1D
-12.7%
1W
-21.0%
1M
+45.5%
6M
+27.9%
YTD
+23.6%
1Y
-32.1%
2Y
+24.2%
5Y
-97.8%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~27% stronger price swings than usual
Ginkgo Bioworks Holdings stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
3 more assignments (Enabler/Second row) Pro-only.
Ginkgo Bioworks operates a cell engineering technology platform that provides solutions for the research, development, and commercialization of biotechnological organisms. The business model encompasses the provision of specialized tools such as functional genomics, antibody development options, AI models, and automated laboratory systems on a technological basis. Additionally, the company offers biomonitoring and bioinformatics services through the Canopy and Horizon platforms to monitor biological threats. The customer base spans diverse industries, including pharma, agriculture, food production, and the defense sector. According to segment data, the revenue model is based entirely on services.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Weak
- Moat
- Narrow
- Moat type
- Switching costs
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Ginkgo Bioworks Holdings
Analyst assessment of Ginkgo Bioworks Holdings
PRICE TARGET LOW
US$5.00
CONSENSUS
US$5.00
MEDIAN
US$5.00
PRICE TARGET HIGH
US$5.00
0
STRONG BUY
4
BUY
3
HOLD
4
SELL
0
STRONG SELL
11
TOTAL · Buy
As of: 13/10/2026
Ginkgo Bioworks Holdings stock metrics
P/E
-2.05
P/B
1.52
EV/EBITDA
-4.18
RETURN ON EQUITY
-11.1%
NET MARGIN
-231.7%
DEBT/EQUITY
0.96
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
72.9%
FLOAT SHARES
49,111,640
AVG. DAILY VOLUME (30D)
2,939,335
Insider transactions (SEC)
Coen Steven P.
HENRY CHRISTIAN O
Coen Steven P.
Coen Steven P.
Coen Steven P.
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -12.7%
Forums (Reddit)
See the full forum history with Pro.
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Ginkgo Bioworks Holdings stock
What does Ginkgo Bioworks Holdings do?
Ginkgo Bioworks Holdings, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Jason Kelly, the company employs around 485 people.
The IPO was on 19/04/2021; the stock trades on NYSE under the ticker DNA.
What do analysts say about Ginkgo Bioworks Holdings stock?
11 analysts rate the stock, the consensus is Buy (as of 13/10/2026).
The average price target is US$5.00, ranging from US$5.00 to US$5.00, with a median of US$5.00.
This is an external assessment, not a statement by Market Jury.
When does Ginkgo Bioworks Holdings report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 27% stronger than usual.
Does Ginkgo Bioworks Holdings pay a dividend?
No, Ginkgo Bioworks Holdings currently does not pay a dividend.
Which stocks are comparable to Ginkgo Bioworks Holdings?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Ginkgo Bioworks Holdings stock analyzed?
Clicking "Analyze stock" lets five strategies assess Ginkgo Bioworks Holdings against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.